Biocon has reported a 15% increase in revenues to INR8.54bn ($134.8m) for the fourth quarter ended March 2015, backed by the strong showing of its IPO-bound research services subsidiary, Syngene, and a 12% growth in its biopharma business.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?